GlobalData on MSN18h
Aclaris Therapeutics secures global rights to Biosion’s antibodies
Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...
Aclaris Therapeutics Up 53%; Analysts' Target Boosts Follow Monday License News
Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...
Aclaris Therapeutics Announces $80 Million Private Placement
WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage ...
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...
Newsable Asianet News on MSN18h
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment Jumps
Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies
Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is ...
The Pharma Letter19h
Aclaris back on track with new money and promising deal
Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...
Aclaris Therapeutics upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Aclaris Therapeutics (ACRS) to Outperform from Market Perform with a price target of $7, up from $2, representing over 120% ...
Pharmabiz5h
Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets
Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...
Aclaris Therapeutics: Promising Pipeline Developments and Strategic Acquisitions Bolster Buy Rating
BTIG analyst Julian Harrison upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of ...
ETF Daily News6d
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Expands By 73.4%
Hedge funds have recently bought and sold shares of the company. BML Capital Management LLC boosted its holdings in Aclaris ...